High-risk multiple myeloma

a multifaceted entity, multiple therapeutic challenges

Eli Muchtar, Hila Magen, Morie Gertz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved, although the true extent of this improvement remains unknown, due to both the heterogeneous components of high-risk disease and its under-representation in clinical trials. In this article, we review the definitions of high-risk disease, emphasizing the fact that no single definition can represent the entire high-risk population. In the second part, we review the treatment options available for the management of high-risk myeloma as well as our general approach for high-risk disease. In light of the poor prognosis associated with high-risk myeloma, even in the current era, new approaches for the management of this subset of patients are needed.

Original languageEnglish (US)
Pages (from-to)1283-1296
Number of pages14
JournalLeukemia and Lymphoma
Volume58
Issue number6
DOIs
StatePublished - Jun 3 2017

Fingerprint

Multiple Myeloma
Therapeutics
Risk Management
Clinical Trials
Population

Keywords

  • combination therapy
  • early-death
  • prognostication
  • progression
  • Resistance
  • transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

High-risk multiple myeloma : a multifaceted entity, multiple therapeutic challenges. / Muchtar, Eli; Magen, Hila; Gertz, Morie.

In: Leukemia and Lymphoma, Vol. 58, No. 6, 03.06.2017, p. 1283-1296.

Research output: Contribution to journalArticle

@article{83ee741d557b4cf2bd06be91e7eb86e4,
title = "High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges",
abstract = "The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved, although the true extent of this improvement remains unknown, due to both the heterogeneous components of high-risk disease and its under-representation in clinical trials. In this article, we review the definitions of high-risk disease, emphasizing the fact that no single definition can represent the entire high-risk population. In the second part, we review the treatment options available for the management of high-risk myeloma as well as our general approach for high-risk disease. In light of the poor prognosis associated with high-risk myeloma, even in the current era, new approaches for the management of this subset of patients are needed.",
keywords = "combination therapy, early-death, prognostication, progression, Resistance, transplant",
author = "Eli Muchtar and Hila Magen and Morie Gertz",
year = "2017",
month = "6",
day = "3",
doi = "10.1080/10428194.2016.1233540",
language = "English (US)",
volume = "58",
pages = "1283--1296",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - High-risk multiple myeloma

T2 - a multifaceted entity, multiple therapeutic challenges

AU - Muchtar, Eli

AU - Magen, Hila

AU - Gertz, Morie

PY - 2017/6/3

Y1 - 2017/6/3

N2 - The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved, although the true extent of this improvement remains unknown, due to both the heterogeneous components of high-risk disease and its under-representation in clinical trials. In this article, we review the definitions of high-risk disease, emphasizing the fact that no single definition can represent the entire high-risk population. In the second part, we review the treatment options available for the management of high-risk myeloma as well as our general approach for high-risk disease. In light of the poor prognosis associated with high-risk myeloma, even in the current era, new approaches for the management of this subset of patients are needed.

AB - The term high-risk multiple myeloma is aimed to identify a heterogeneous group of patients who are more likely to progress and die early of their disease. Therefore, recognition of these patients is crucial. With the increase in the number of treatment options, the outcome for high-risk patients has probably improved, although the true extent of this improvement remains unknown, due to both the heterogeneous components of high-risk disease and its under-representation in clinical trials. In this article, we review the definitions of high-risk disease, emphasizing the fact that no single definition can represent the entire high-risk population. In the second part, we review the treatment options available for the management of high-risk myeloma as well as our general approach for high-risk disease. In light of the poor prognosis associated with high-risk myeloma, even in the current era, new approaches for the management of this subset of patients are needed.

KW - combination therapy

KW - early-death

KW - prognostication

KW - progression

KW - Resistance

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=84991031529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991031529&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1233540

DO - 10.1080/10428194.2016.1233540

M3 - Article

VL - 58

SP - 1283

EP - 1296

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -